| Autor: |
Bleve A; Humanitas Clinical and Research Center-IRCCS, 20089 Rozzano, Italy., Consonni FM; Department of Pharmaceutical Sciences, Università del Piemonte Orientale 'Amedeo Avogadro', 28100 Novara, Italy., Porta C; Department of Pharmaceutical Sciences, Università del Piemonte Orientale 'Amedeo Avogadro', 28100 Novara, Italy.; Center for Translational Research on Autoimmune & Allergic Diseases (CAAD), Università del Piemonte Orientale 'Amedeo Avogadro', 28100 Novara, Italy., Garlatti V; Department of Pharmaceutical Sciences, Università del Piemonte Orientale 'Amedeo Avogadro', 28100 Novara, Italy., Sica A; Humanitas Clinical and Research Center-IRCCS, 20089 Rozzano, Italy.; Department of Pharmaceutical Sciences, Università del Piemonte Orientale 'Amedeo Avogadro', 28100 Novara, Italy. |
| Abstrakt: |
In recent years, the immune system has emerged as a critical regulator of tumor development, progression and dissemination. Advanced therapeutic approaches targeting immune cells are currently under clinical use and improvement for the treatment of patients affected by advanced malignancies. Among these, anti-PD1/PD-L1 and anti-CTLA4 immune checkpoint inhibitors (ICIs) are the most effective immunotherapeutic drugs at present. In spite of these advances, great variability in responses to therapy exists among patients, probably due to the heterogeneity of both cancer cells and immune responses, which manifest in diverse forms in the tumor microenvironment (TME). The variability of the immune profile within TME and its prognostic significance largely depend on the frequency of the infiltrating myeloid cells, which often represent the predominant population, characterized by high phenotypic heterogeneity. The generation of heterogeneous myeloid populations endowed with tumor-promoting activities is typically promoted by growing tumors, indicating the sequential levels of myeloid reprogramming as possible antitumor targets. This work reviews the current knowledge on the events governing protumoral myelopoiesis, analyzing the mechanisms that drive the expansion of major myeloid subsets, as well as their functional properties, and highlighting recent translational strategies for clinical developments. |
